Literature DB >> 12941379

Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?

Michael Madeja1, Doru Georg Margineanu, Ali Gorji, Elke Siep, Paul Boerrigter, Henrik Klitgaard, Erwin-Josef Speckmann.   

Abstract

Levetiracetam (ucb L059; Keppra) is a novel antiepileptic drug. Its effects on action potential generation and voltage-operated potassium currents were studied in acutely isolated hippocampal CA1 neurones from rat and guinea pig, using the patch-clamp technique in the whole-cell configuration. (i) Levetiracetam reduced repetitive action potential generation and affected the single action potential. Levetiracetam, 100 microM, decreased the total number of action potentials and reduced the total depolarisation area of repetitive action potentials by 21%. Furthermore, levetiracetam increased the duration of the first action potential slightly, prolonged that of the second action potential by 13% and decreased the slope of rise by 23%. (ii) Levetiracetam decreased the voltage-operated potassium current. Without effect on sodium and A-type potassium currents, levetiracetam, 100 microM, reduced the delayed rectifier current by 26%. The concentration of half-maximal block was 47 microM for guinea pig and 6 microM for rat neurones. Thus, the reduction of repetitive action potential generation by levetiracetam can be attributed, unexpectedly, to a moderate reduction of the delayed rectifier potassium current, as supported by a simulation of action potential generation. This suggests that a reduction of potassium currents may contribute to the antiepileptic effect(s) of levetiracetam.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941379     DOI: 10.1016/s0028-3908(03)00248-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  24 in total

1.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

2.  Prediction of off-target drug effects through data fusion.

Authors:  Emmanuel R Yera; Ann E Cleves; Ajay N Jain
Journal:  Pac Symp Biocomput       Date:  2014

Review 3.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

4.  Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus.

Authors:  Jonathan Robitsek; Marcia H Ratner; Tara Stewart; Howard Eichenbaum; David H Farb
Journal:  Hippocampus       Date:  2015-07-14       Impact factor: 3.899

5.  Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus.

Authors:  Chun-Yao Lee; Chih-Chuan Chen; Horng-Huei Liou
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 6.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 7.  Levetiracetam in neonatal seizures: a review.

Authors:  Allison L Mruk; Karen L Garlitz; Noelle R Leung
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

8.  Levetiracetam inhibits Na+-dependent Cl-/HCO3- exchange of adult hippocampal CA3 neurons from guinea-pigs.

Authors:  Tobias Leniger; Jan Thöne; Udo Bonnet; Andreas Hufnagel; Dieter Bingmann; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

9.  In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-active drugs.

Authors:  Pierangelo Sardo; Stefania D'Agostino; Valerio Rizzo; Fabio Carletti; Gioacchino Lonobile; Giuseppe Ferraro
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

Review 10.  Emerging treatments for progressive myoclonus epilepsies.

Authors:  Antonella Riva; Alberto Guglielmo; Ganna Balagura; Francesca Marchese; Elisabetta Amadori; Michele Iacomino; Berge Arakel Minassian; Federico Zara; Pasquale Striano
Journal:  Expert Rev Neurother       Date:  2020-03-17       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.